Optimal Chemotherapy for Recurrent Ovarian Cancer
... randomized controlled clinical trials (RCTs), if appropriate. o If the option to participate in an RCT is not available, combination platinum-based chemotherapy should be considered, providing that there are no contraindications. The decision regarding which combination to use should be based on the ...
... randomized controlled clinical trials (RCTs), if appropriate. o If the option to participate in an RCT is not available, combination platinum-based chemotherapy should be considered, providing that there are no contraindications. The decision regarding which combination to use should be based on the ...
Levonorgestrel - Therapeutic Goods Administration
... The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. ...
... The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. ...
November 2014 PBAC Meeting
... financial implications to the PBS and changes in PBS usage. To further ensure that the PBS listing of sorafenib for second line treatment in renal cell carcinoma meets the intent of a cost-minimisation recommendation, the PBAC advised that sorafenib should join the risk sharing arrangement currently ...
... financial implications to the PBS and changes in PBS usage. To further ensure that the PBS listing of sorafenib for second line treatment in renal cell carcinoma meets the intent of a cost-minimisation recommendation, the PBAC advised that sorafenib should join the risk sharing arrangement currently ...
product monograph
... Clostridium difficile-associated disease (CDAD) has been reported with use of many antibacterial agents, including ertapenem. CDAD may range in severity from mild diarrhea to fatal colitis. It is important to consider this diagnosis in patients who present with diarrhea, or symptoms of colitis, pseu ...
... Clostridium difficile-associated disease (CDAD) has been reported with use of many antibacterial agents, including ertapenem. CDAD may range in severity from mild diarrhea to fatal colitis. It is important to consider this diagnosis in patients who present with diarrhea, or symptoms of colitis, pseu ...
Matrix metalloproteinase inhibitors in rheumatic diseases
... therapeutic focus of these inhibitors has been directed at preventing metastatic growth and related angiogenesis where MMPs are considered crucial. Development of MMP inhibitors has been based on known interactions between the enzyme and their substrates/inhibitors in order to design molecules that ...
... therapeutic focus of these inhibitors has been directed at preventing metastatic growth and related angiogenesis where MMPs are considered crucial. Development of MMP inhibitors has been based on known interactions between the enzyme and their substrates/inhibitors in order to design molecules that ...
A multicentre randomised controlled trial of the use of continuous
... Second, the HTA programme provides grants for clinical trials for researchers who identify research questions. These are assessed for importance to patients and the NHS, and scientific rigour. Third, through its Technology Assessment Report (TAR) call-off contract, the HTA programme commissions besp ...
... Second, the HTA programme provides grants for clinical trials for researchers who identify research questions. These are assessed for importance to patients and the NHS, and scientific rigour. Third, through its Technology Assessment Report (TAR) call-off contract, the HTA programme commissions besp ...
HIGHLIGHTS OF PRESCRIBING
... Sumavel DosePro is contraindicated in patients with ischemic or vasospastic CAD. There have been rare reports of serious cardiac adverse reactions, including acute myocardial infarction, occurring within a few hours following administration of Sumavel DosePro. Some of these reactions occurred in pat ...
... Sumavel DosePro is contraindicated in patients with ischemic or vasospastic CAD. There have been rare reports of serious cardiac adverse reactions, including acute myocardial infarction, occurring within a few hours following administration of Sumavel DosePro. Some of these reactions occurred in pat ...
Current clinical trials in LAM
... regulators, aromatase inhibitors) within 30 days month of registration • Medical or psychiatric conditions that would interfere with the ability to provide informed consent. ...
... regulators, aromatase inhibitors) within 30 days month of registration • Medical or psychiatric conditions that would interfere with the ability to provide informed consent. ...
Product Monograph - Ask Novartis Pharma
... There have been reports of serious atrial fibrillation in patients treated with zoledronic acid. Atrial fibrillation may occur at any time during treatment Overall incidence of atrial fibrillation in the 3-year postmenopausal osteoporosis trial (HORIZON-PFT) using ACLASTA® (zoledronic acid) 5 mg dos ...
... There have been reports of serious atrial fibrillation in patients treated with zoledronic acid. Atrial fibrillation may occur at any time during treatment Overall incidence of atrial fibrillation in the 3-year postmenopausal osteoporosis trial (HORIZON-PFT) using ACLASTA® (zoledronic acid) 5 mg dos ...
Pharmacotherapy of Autism Spectrum Disorders: A Small Piece of
... Reason for use: Frequently observed dietary deficiency of vitamins/micronutrients in children with ASD Combined Vitamin B6-Magnesium Cochrane review of 3 randomized trials: Data could not be meta-analyzed due to significant heterogeneity All 3 trials reported no significant difference co ...
... Reason for use: Frequently observed dietary deficiency of vitamins/micronutrients in children with ASD Combined Vitamin B6-Magnesium Cochrane review of 3 randomized trials: Data could not be meta-analyzed due to significant heterogeneity All 3 trials reported no significant difference co ...
Fentanyl - Queensland Ambulance Service
... While effort has been made to contact all copyright owners this has not always been possible. The QAS would welcome notification from any copyright holder who has been omitted or incorrectly acknowledged. All feedback and suggestions are welcome, please forward to: Clinical.Guidelines@ambulance.qld. ...
... While effort has been made to contact all copyright owners this has not always been possible. The QAS would welcome notification from any copyright holder who has been omitted or incorrectly acknowledged. All feedback and suggestions are welcome, please forward to: Clinical.Guidelines@ambulance.qld. ...
Review article: the current pharmacological therapies for hepatic
... (<0.4%) with broad-spectrum in vitro activity against enteric bacteria.19–22 The tolerability profile of rifaximin is comparable to placebo,22 and no clinical drug interactions have been reported.21 Because of the lack of systemic accumulation with rifaximin,20 no dosing adjustments are required in ...
... (<0.4%) with broad-spectrum in vitro activity against enteric bacteria.19–22 The tolerability profile of rifaximin is comparable to placebo,22 and no clinical drug interactions have been reported.21 Because of the lack of systemic accumulation with rifaximin,20 no dosing adjustments are required in ...
The Spirogram IDIOPATHIC PULMONARY FIBROSIS: New Approaches to Therapy
... with oxygen, exercise, cough suppressants, and similar measures is often helpful in relieving symptoms but does not reverse the scarring process. Although several forms of therapy have been used to treat IPF over the past three decades, none have been shown clearly to be effective in randomized plac ...
... with oxygen, exercise, cough suppressants, and similar measures is often helpful in relieving symptoms but does not reverse the scarring process. Although several forms of therapy have been used to treat IPF over the past three decades, none have been shown clearly to be effective in randomized plac ...
Pipeline/Commercial Insight: Molecular Targeted Cancer
... Key findings and highlights • In 2005, the MTT market was worth $7.5 billion and the forecast sales of already marketed drugs in this class are expected to grow to $25.2 billion by 2015, at a CAGR of 12.9 per cent. This growth will be driven mainly by Genentech/Roche's Rituxan, Herceptin and Avastin ...
... Key findings and highlights • In 2005, the MTT market was worth $7.5 billion and the forecast sales of already marketed drugs in this class are expected to grow to $25.2 billion by 2015, at a CAGR of 12.9 per cent. This growth will be driven mainly by Genentech/Roche's Rituxan, Herceptin and Avastin ...
Presented at ICAAC 2015, San Diego, CA, USA
... Methods. A double-blind, placebo-controlled, single dose escalation study in healthy volunteers. Eligible subjects were aged 18–55 y, male or female of non-childbearing potential. They were assigned to 6 dosing cohorts (80, 160, 320, 480, 640 and 800 mg of Debio 1450), each with 8 subjects (6 random ...
... Methods. A double-blind, placebo-controlled, single dose escalation study in healthy volunteers. Eligible subjects were aged 18–55 y, male or female of non-childbearing potential. They were assigned to 6 dosing cohorts (80, 160, 320, 480, 640 and 800 mg of Debio 1450), each with 8 subjects (6 random ...
6279.02: adult respiratory distress
... However, the EHS guidance is advisory and has been developed to assist healthcare professionals, together with patients, to make decisions about the management of the patient’s health, including treatments. It is intended to support the decision making process and is not a substitute for sound clini ...
... However, the EHS guidance is advisory and has been developed to assist healthcare professionals, together with patients, to make decisions about the management of the patient’s health, including treatments. It is intended to support the decision making process and is not a substitute for sound clini ...
Options of drugs for intermittent presumptive treatment for malaria in
... five years treated with SP were still parasitaemic 7 days after treatment. 18 In a further study undertaken in the same area in 2002, 42% of children treated with SP were parasitaemic on day 14 (Mutabingwa, personal communication). In southern Tanzania, a study conducted in 1999 showed a lower, but ...
... five years treated with SP were still parasitaemic 7 days after treatment. 18 In a further study undertaken in the same area in 2002, 42% of children treated with SP were parasitaemic on day 14 (Mutabingwa, personal communication). In southern Tanzania, a study conducted in 1999 showed a lower, but ...
Harnessing the placebo effect - Philosophical Transactions of the
... historically administered to placate patients and comply with their wishes to receive medications. (Most pharmacological placebos in clinical trials are also pure placebos.) Impure placebos are treatment interventions that typically have a specific active principle that is known to be effective in c ...
... historically administered to placate patients and comply with their wishes to receive medications. (Most pharmacological placebos in clinical trials are also pure placebos.) Impure placebos are treatment interventions that typically have a specific active principle that is known to be effective in c ...
Music interventions for mechanically ventilated
... 2010). We handsearched music therapy journals and reference lists and contacted relevant experts to identify unpublished manuscripts. There was no language restriction. Selection criteria We included all randomized and quasi-randomized controlled trials that compared music interventions and standard ...
... 2010). We handsearched music therapy journals and reference lists and contacted relevant experts to identify unpublished manuscripts. There was no language restriction. Selection criteria We included all randomized and quasi-randomized controlled trials that compared music interventions and standard ...
Options for patients with irritable bowel syndrome
... Symptoms experienced by persons with IBS significantly impact quality-of-life.9 Studies using general or disease-specific quality-of-life instruments have consistently shown that the health status of those with IBS is poorer than that of the general population.10–12 Quality-of-life scores of IBS pat ...
... Symptoms experienced by persons with IBS significantly impact quality-of-life.9 Studies using general or disease-specific quality-of-life instruments have consistently shown that the health status of those with IBS is poorer than that of the general population.10–12 Quality-of-life scores of IBS pat ...
Extract from the Clinical Evaluation Report for Elosulfase alfa (rch)
... Second round benefit-risk assessment ___________________________ 72 12.1. Second round assessment of benefits _____________________________________ 72 12.2. Second round assessment of risks ________________________________________ 72 12.3. Second round assessment of benefit-risk balance ____________ ...
... Second round benefit-risk assessment ___________________________ 72 12.1. Second round assessment of benefits _____________________________________ 72 12.2. Second round assessment of risks ________________________________________ 72 12.3. Second round assessment of benefit-risk balance ____________ ...
... ecology, has no adverse side-effects, as is often associated with many antimicrobial agents, and is compatible with the anionic components of fluoride dentifrices.5,6 Furthermore, the addition of triclosan to oral care products has been shown to reduce dental plaque, gingivitis and calculus.6 Howeve ...
product information - Medicines Information
... following reversal of neuromuscular blockade. Even if recovery from neuromuscular blockade is complete, other drugs used in the peri- and postoperative period could depress respiratory function and therefore ventilatory support might still be required. Should neuromuscular blockade recur following e ...
... following reversal of neuromuscular blockade. Even if recovery from neuromuscular blockade is complete, other drugs used in the peri- and postoperative period could depress respiratory function and therefore ventilatory support might still be required. Should neuromuscular blockade recur following e ...
Drug-coated balloon treatment for lower extremity vascular disease
... without stent placement. At the 6-month follow-up, patients with dissection of any grade after treatment with coated balloons (n ¼ 43) had significantly lower LLL than patients with dissection after POBA (n ¼ 43, 0.4 vs. 1.9 mm, P ¼ 0.001). Interestingly, especially patients with severe dissections ...
... without stent placement. At the 6-month follow-up, patients with dissection of any grade after treatment with coated balloons (n ¼ 43) had significantly lower LLL than patients with dissection after POBA (n ¼ 43, 0.4 vs. 1.9 mm, P ¼ 0.001). Interestingly, especially patients with severe dissections ...
Slide 1 - The Ophthalmology Report 2013
... There was no significant difference among all study groups in terms of the number of eyes that lost or gained 15 letters of visual acuity. » Patients randomized to as-needed treatment with bevacizumab received more injections (mean, 7.7) than did those given as-needed ranibizumab (mean, 6.9). ...
... There was no significant difference among all study groups in terms of the number of eyes that lost or gained 15 letters of visual acuity. » Patients randomized to as-needed treatment with bevacizumab received more injections (mean, 7.7) than did those given as-needed ranibizumab (mean, 6.9). ...